Self-collected versus clinician-collected anal swabs for HPV screening in people living with HIV in Réunion
Official title: Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV
Run by Centre Hospitalier Universitaire de la Réunion · NCT06507917 · Data updated 2026-11-12
This study tries to see if people living with HIV aged 30 and older can collect their own anal swab as accurately and comfortably as a healthcare professional for HPV screening.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years and up |
| Sex | All |
| Enrollment | 398 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 2 sites (Saint-Denis and 1 other locations) |
| Status | Recruiting |
| Started | November 28, 2025 |
| Main results expected | December 28, 2026 |
| Study ends | January 2, 2027 |
| Registry record updated | December 11, 2025 |
| Trial ID | NCT06507917 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people living with HIV aged 30 or older who live on Réunion Island, are followed at the CHU de la Réunion, can perform self-sampling, can complete a questionnaire, and can give informed consent.
✕Probably not a fit
People with a known current diagnosis of anal cancer, a recent anal swab within 7 days, minors, those under legal protection, or individuals unable to perform self-sampling are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial enrolls people living with HIV aged 30 and over who are followed at the University Hospital of Réunion and asks participants to provide an anal self-swab as well as a clinician-collected swab. Samples will be tested for oncogenic HPV types (notably HPV-16) and the results from self-collection and clinician collection will be compared for concordance. Participants will also complete a questionnaire about the acceptability and ease of self-sampling. The goal is to determine whether self-sampling could be a reliable, acceptable option to expand anal HPV screening in this high-risk population on Réunion Island.
Why it matters
Potential benefit: If successful, self-sampling could increase access to anal HPV screening, leading to earlier detection and treatment of precancerous lesions in people living with HIV.
How similar studies have gone: Previous studies of self-collected genital and anal HPV samples, including work in people living with HIV and MSM, have shown promising concordance and acceptability, but results vary by population and setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient : * living with HIV * aged 30 or over * resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island) * Able to perform anal self-sampling * Able to answer a questionnaire * Affiliated with or benefiting from a social security scheme * Have given free, informed and signed consent Exclusion Criteria: * People with a previous anal swab less than 7 days old * Persons with a known current diagnosis of anal cancer * Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators
Where it's running
-
CHU de la Réunion Recherche Clinique
Saint-Pierre, Reunion Recruiting -
CHU de la Réunion Recherche Clinique
Saint-Denis, Reunion Not yet recruiting
Study contacts
- Study coordinator: Lucie AUZANNEAU
- Email: lucie.auzanneau@chu-reunion.fr
- Phone: 0262394999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of cervical cancer after HPV detection in healthy women
This study tests how likely it is for cervical cancer to develop after different HPV detection patterns in healthy women who undergo HPV-based screening.
-
Dysplasix™ intravaginal suppositories for women with high‑risk HPV and mild cervical cell changes
This trial tests whether nightly Dysplasix™ vaginal suppositories can clear high‑risk HPV and help mild cervical cell changes (ASC‑US or LSIL) in adult women.
-
At-home HPV self-collection kits for cervical cancer screening
We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.
-
Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV
This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.
-
CHW4CervixHealth: HPV self-collection kits with community health workers
This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.
-
Q-Pad menstrual-pad test to detect high-risk HPV and cervical precancer
This study tests whether a home menstrual-pad kit (Q-Pad) can detect high-risk HPV and cervical precancer in people referred for colposcopy after an abnormal Pap or HPV result.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.